Why the study?
Aldosterone-renin ratio is an important screening tool for primary aldosteronism in secondary hypertension, but its prevalence among Iraqi hypertensive patients needed to be measured.
Observational (n=150)
No
In a tertiary center in Iraq, 26% of hypertensive patients screened for secondary causes had an elevated aldosterone-renin ratio, emphasizing the need for primary aldosteronism screening in high-risk hypertension.
BACKGROUND AND AIM: Aldosterone-renin ratio (ARR) is an important screening tool for the assessment of primary aldosteronism as a cause of secondary hypertension. This study aimed to measure the prevalence of patients with elevated ARR among samples of Iraqi patients with hypertension. METHODS: A retrospective study was conducted at Faiha Specialized Diabetes, Endocrine and Metabolism Center (FDEMC) in Basrah during the period of February 2020 to November 2021. We evaluated the records of patients with hypertension whom were screened for endocrine cause, and an ARR cut-off equal or more than 5.7 was considered elevated. RESULTS: Of the total 150 patients enrolled, 39 (26%) of them had an elevated ARR. No statistically significant association for the elevated ARR with age, gender, BMI, duration of hypertension, systolic and diastolic blood pressure, pulse rate, and presence or absence of diabetes mellitus or lipid profile. CONCLUSION: High frequency of elevated ARR was seen in 26% of patients with hypertension. More studies need to be conducted in the future taking larger samples.
No takes yet. Share an insight, caveat, or question.
Zwain et al. (2023) conducted an observational in Hypertension (n=150). Aldosterone-renin ratio (ARR) screening was evaluated on Prevalence of elevated ARR (≥ 5.7).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: